Clinical Prior Authorization
The Clinical Prior Authorization (PA) Program was implemented to improve quality and manage drug classes that have been identified as requiring additional monitoring. This program is also intended as a means of ensuring that drugs are being prescribed for the right patients and for the appropriate reasons, while still monitoring drug expenditures.
Clinical Prior Authorization Request Forms
- Anti-Obesity Medication

- Benign Prostatic Hyperplasia (BPH)

- Bowel Disorders

- Brand Name Drug Approval

- CNS Stimulant/ADHD Medication Approval

- Cymbalta ®

- Dipeptidyl Peptidase - 4 Inhibitors & Combination Medications

- Direct Renin Inhibitor Medications

- Fibromyalgia Criteria

- Glucagon-like Peptide (GLP-1) Receptor Agonist (formerly Byetta)

- Gout Medication

- Growth Hormone

- Hematopoietic Agents

- Hepatitis C

- Huntington's Disease Medications

- Hyaluronic Acid Derivatives Injection

- Legend Topical NSAIDS

- Lyrica ®

- Onychomycosis Agents Approval

- Oral Isotretinoin

- Oral Multiple Sclerosis Medications

- Oral NSAIDS Legend

- Oxycontin

- Proton Pump Inhibitor Approval

- Receptor Selective NSAID Authorization

- Restless Leg Syndrome Medication

- Spiriva ®

- Suboxone ®

- Symlin ®

- Synagis

- Systemic Immunomodulators

- Topical Combination Acne Products

- Topical Immunomodulators

- Transmucosal Analgesic

- Xenical ®

- Xolair ®

|
|
|
|
Adobe Acrobat Reader format. You can download a free reader from Adobe.
